Drug Profile
SYL 116011
Alternative Names: SYL-116011Latest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator Sylentis
- Class Eye disorder therapies; Gene therapies; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Allergic conjunctivitis
Most Recent Events
- 05 Sep 2023 SYL 116011 is still in preclinical trials for Allergic conjunctivitis in Spain (unspecified route) (Sylentis pipeline, September 2023)
- 12 Jul 2016 Preclinical trials in Allergic conjunctivitis in Spain (unspecified route)